• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Unproven Treatments

Background

Because there is no cure for ALS/MND, and approved treatments have a limited effect, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety, and in none has a benefit been shown in rigorous scientific studies. Furthermore, these treatments are often extremely expensive, and they are marketed to people who are looking for options. Many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Unproven treatments are sometimes called alternative or off-label treatments. Examples include, but are not limited to: stem cell clinics; holistic, naturopathic, homeopathic, and traditional medicine; and dietary or physical therapy regimens.

Resources like ALSUntangled can be valuable for balanced, open-access information about such alternative treatments, and ClinicalTrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

The ALSUntangled article “Ten red flags”—things to be wary of in alternative or off-label products—provides a helpful guide to the warning signs to look out for in an advertised potential treatment. Read the “Ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved, unproven, or off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like ClinicalTrials.gov is encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician, and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there were anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

International Alliance of ALS/MND Associations
June 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Mike Cels, Canada

    Mike Cels, Canada

  • Liam Dwyer, England

    Liam Dwyer, England

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Phil Rossall, UK

    Phil Rossall, UK

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • JP

    JP

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • John Russo, USA

    John Russo, USA
    final3878

  • Jack Buzby, USA

    Jack Buzby, USA

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Glen Elison, USA

    Glen Elison, USA

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Jose Rivero Muñoz, Mexico

    Jose Rivero Muñoz, Mexico

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Jan Zuring, Netherlands

    Jan Zuring, Netherlands

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • John Dinon, Australia

    John Dinon, Australia

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Jason Goodman, USA

    Jason Goodman, USA

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Purningam Jacob, India

    Purningam Jacob, India

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Ali Var, Turkey

    Ali Var, Turkey

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login